Table 6 Efficacies of serum Egfl7, AFP or Parallel in distinguishing early HCC patients from non-HCC individuals
Data | Testing Cohort | Validation Cohort | ||||
|---|---|---|---|---|---|---|
Egfl7 | AFP | Parallel | Egfl7 | AFP | Parallel | |
Sensitivity | 76.6% | 64% | 91% | 75.9% | 58.9% | 86.7% |
Specificity | 82.7% | 68% | 66% | 76.0% | 81.2% | 62.3% |
Accuracy | 79.9% | 66.1% | 77.6% | 76.0% | 73.3% | 70.9% |
Omission diagnostic rate | 23.4% | 36% | 9% | 24.1% | 41.1% | 13.3% |
Mistake diagnostic rate | 17.3% | 32% | 34% | 24.0% | 18.8% | 37.7% |
Positive likelihood ratio | 4.44 | 2.0 | 2.6 | 3.16 | 3.13 | 2.30 |
Negative likelihood ratio | 0.28 | 0.53 | 0.14 | 0.32 | 0.51 | 0.21 |
Positive predict value | 0.80 | 0.64 | 0.70 | 0.63 | 0.63 | 0.55 |
Negative predict value | 0.79 | 0.68 | 0.89 | 0.85 | 0.78 | 0.90 |